278 related articles for article (PubMed ID: 24632713)
1. Targeting MUC1-C is synergistic with bortezomib in downregulating TIGAR and inducing ROS-mediated myeloma cell death.
Yin L; Kufe T; Avigan D; Kufe D
Blood; 2014 May; 123(19):2997-3006. PubMed ID: 24632713
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of the MUC1-C oncoprotein induces multiple myeloma cell death by down-regulating TIGAR expression and depleting NADPH.
Yin L; Kosugi M; Kufe D
Blood; 2012 Jan; 119(3):810-6. PubMed ID: 22117045
[TBL] [Abstract][Full Text] [Related]
3. Targeting MUC1-C inhibits the AKT-S6K1-elF4A pathway regulating TIGAR translation in colorectal cancer.
Ahmad R; Alam M; Hasegawa M; Uchida Y; Al-Obaid O; Kharbanda S; Kufe D
Mol Cancer; 2017 Feb; 16(1):33. PubMed ID: 28153010
[TBL] [Abstract][Full Text] [Related]
4. Bortezomib resistance and MUC1 in myeloma.
Grant S
Blood; 2014 May; 123(19):2910-2. PubMed ID: 24810626
[No Abstract] [Full Text] [Related]
5. MUC1-C is a target in lenalidomide resistant multiple myeloma.
Yin L; Tagde A; Gali R; Tai YT; Hideshima T; Anderson K; Avigan D; Kufe D
Br J Haematol; 2017 Sep; 178(6):914-926. PubMed ID: 28643330
[TBL] [Abstract][Full Text] [Related]
6. Mucin 1 is a potential therapeutic target in cutaneous T-cell lymphoma.
Jain S; Stroopinsky D; Yin L; Rosenblatt J; Alam M; Bhargava P; Clark RA; Kupper TS; Palmer K; Coll MD; Rajabi H; Pyzer A; Bar-Natan M; Luptakova K; Arnason J; Joyce R; Kufe D; Avigan D
Blood; 2015 Jul; 126(3):354-62. PubMed ID: 26048911
[TBL] [Abstract][Full Text] [Related]
7. Combination chemotherapy increases cytotoxicity of multiple myeloma cells by modification of nuclear factor (NF)-κB activity.
Salem K; Brown CO; Schibler J; Goel A
Exp Hematol; 2013 Feb; 41(2):209-18. PubMed ID: 23063726
[TBL] [Abstract][Full Text] [Related]
8. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
Pei XY; Dai Y; Grant S
Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
[TBL] [Abstract][Full Text] [Related]
9. The histone deacetylase inhibitor, PXD101, potentiates bortezomib-induced anti-multiple myeloma effect by induction of oxidative stress and DNA damage.
Feng R; Oton A; Mapara MY; Anderson G; Belani C; Lentzsch S
Br J Haematol; 2007 Nov; 139(3):385-97. PubMed ID: 17910628
[TBL] [Abstract][Full Text] [Related]
10. ROS Overproduction Sensitises Myeloma Cells to Bortezomib-Induced Apoptosis and Alleviates Tumour Microenvironment-Mediated Cell Resistance.
Caillot M; Zylbersztejn F; Maitre E; Bourgeais J; Hérault O; Sola B
Cells; 2020 Oct; 9(11):. PubMed ID: 33114738
[TBL] [Abstract][Full Text] [Related]
11. Characterization of bortezomib-adapted I-45 mesothelioma cells.
Zhang L; Littlejohn JE; Cui Y; Cao X; Peddaboina C; Smythe WR
Mol Cancer; 2010 May; 9():110. PubMed ID: 20482802
[TBL] [Abstract][Full Text] [Related]
12. TM-233, a novel analog of 1'-acetoxychavicol acetate, induces cell death in myeloma cells by inhibiting both JAK/STAT and proteasome activities.
Sagawa M; Tabayashi T; Kimura Y; Tomikawa T; Nemoto-Anan T; Watanabe R; Tokuhira M; Ri M; Hashimoto Y; Iida S; Kizaki M
Cancer Sci; 2015 Apr; 106(4):438-46. PubMed ID: 25613668
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of MUC1-C regulates metabolism by AKT pathway in esophageal squamous cell carcinoma.
GongSun X; Zhao Y; Jiang B; Xin Z; Shi M; Song L; Qin Q; Wang Q; Liu X
J Cell Physiol; 2019 Jul; 234(7):12019-12028. PubMed ID: 30523643
[TBL] [Abstract][Full Text] [Related]
14. Norcantharidin enhances bortezomib-antimyeloma activity in multiple myeloma cells in vitro and in nude mouse xenografts.
Du HF; Yu LJ; Meng YF; Lv HY; Meng J; Song XN; Zhang JQ
Leuk Lymphoma; 2013 Mar; 54(3):607-18. PubMed ID: 22889356
[TBL] [Abstract][Full Text] [Related]
15. Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells.
Chauhan D; Li G; Podar K; Hideshima T; Mitsiades C; Schlossman R; Munshi N; Richardson P; Cotter FE; Anderson KC
Blood; 2004 Oct; 104(8):2458-66. PubMed ID: 15217830
[TBL] [Abstract][Full Text] [Related]
16. Arsenic trioxide and bortezomib interact synergistically to induce apoptosis in chronic myelogenous leukemia cells resistant to imatinib mesylate through Bcr/Abl‑dependent mechanisms.
Xu W; Wei W; Yu Q; Wu C; Ye C; Wu Y; Yan H
Mol Med Rep; 2014 Sep; 10(3):1519-24. PubMed ID: 24939418
[TBL] [Abstract][Full Text] [Related]
17. Shikonin, dually functions as a proteasome inhibitor and a necroptosis inducer in multiple myeloma cells.
Wada N; Kawano Y; Fujiwara S; Kikukawa Y; Okuno Y; Tasaki M; Ueda M; Ando Y; Yoshinaga K; Ri M; Iida S; Nakashima T; Shiotsu Y; Mitsuya H; Hata H
Int J Oncol; 2015 Mar; 46(3):963-72. PubMed ID: 25530098
[TBL] [Abstract][Full Text] [Related]
18. A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells.
Chauhan D; Li G; Podar K; Hideshima T; Neri P; He D; Mitsiades N; Richardson P; Chang Y; Schindler J; Carver B; Anderson KC
Cancer Res; 2005 Sep; 65(18):8350-8. PubMed ID: 16166312
[TBL] [Abstract][Full Text] [Related]
19. Tp53-induced glycolysis and apoptosis regulator (TIGAR) protects glioma cells from starvation-induced cell death by up-regulating respiration and improving cellular redox homeostasis.
Wanka C; Steinbach JP; Rieger J
J Biol Chem; 2012 Sep; 287(40):33436-46. PubMed ID: 22887998
[TBL] [Abstract][Full Text] [Related]
20. Copper-zinc superoxide dismutase-mediated redox regulation of bortezomib resistance in multiple myeloma.
Salem K; McCormick ML; Wendlandt E; Zhan F; Goel A
Redox Biol; 2015; 4():23-33. PubMed ID: 25485927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
